Video

Q&A with Alain Litwin, MD, from Albert Einstein College of Medicine: Studying and Overcoming Stigmas of Treating Injectable Drug Users with Hepatitis C

Author(s):

One of the largest populations of patients with hepatitis C is those who use injectable drugs. Despite this, many of these patients do not receive the medications they need to treat their conditions.

One of the largest populations of patients with hepatitis C is those who use injectable drugs. Despite this many of these patients do not receive the medications they need to treat their conditions.

Alain H. Litwin, MD, from the Albert Einstein College of Medicine discussed the results of research done on the topic and what it can mean for providing care for these patients during the annual Liver Meeting in San Francisco.

As hepatitis C becomes a more treatable condition work is being done to extend the treatment to as many patients as possible, including current and former injectable drug users.

Related Videos
Caroline Piatek, MD: High HCRU, Patient Concerns Highlight Great Unmet Need in wAIHA
Steven W. Pipe, MD: Supporting Gene Therapy Implementation for Hemophilia
Corinna L. Schultz, MD: Improving Sickle Cell Trait Documentation in Infancy
Sibgha Zaheer, MD: Determining Washout Period With Fitusiran, Emicizumab Transition for Hemophilia
Pavan K. (Tem) Bendapudi, MD: Large-Scale Analyses Elucidate Genetic Risk of Thrombosis
Seema Rani, MD: Examining Sleep Health in Youth With SCD
Daniel Wang: A More Appropriate Ferritin Threshold is Cost-Effective for Iron Deficiency Screening
Kimberly A. Davidow, MD: Elucidating Risk of Autoimmune Disease in Childhood Cancer Survivors
Yehuda Handelsman, MD: Insulin Resistance in Cardiometabolic Disease and DCRM 2.0 | Image Credit: TMIOA
© 2025 MJH Life Sciences

All rights reserved.